February 2, 2017 10:49 AM EST

J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments

Shehla Shakoor

Managing Director

• J&J is making some new investments in microbiome research, including adding Caelus Health to its J&J Innovation portfolio. “These collaborations and investments will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

J&J makes new in­vest­ments in mi­cro­bio­me R&D; UK’s Ar­ix out to raise £100 mil­lion for new biotech in­vest­ments

Managing Director

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments